Clene Inc. Total Liabilities
Clene Inc. total liabilities. Based on the latest financial reports, Clene Inc. (CLNN) has total liabilities worth $47.82 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CLNN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Clene Inc. (2018–2025)
Total liabilities of Clene Inc. from 2018 to 2025. This chart illustrates how Clene Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Clene Inc. Competitors by Total Liabilities
The table below lists competitors of Clene Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Changhae Ethanol Co. Ltd
KQ:004650
|
Korea | ₩52.91 Billion |
|
AGX Group Berhad
KLSE:0299
|
Malaysia | RM93.51 Million |
|
Atende S.A.
WAR:ATD
|
Poland | zł126.94 Million |
|
Francotyp-Postalia Holding AG
F:FPH
|
Germany | €113.20 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €53.74 Million |
|
Helium Evolution Inc
V:HEVI
|
Canada | CA$1.39 Million |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
Korea | ₩18.23 Billion |
|
RSUPPORT Co. Ltd
KQ:131370
|
Korea | ₩15.47 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Clene Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Clene Inc. balance sheet assets.
Liquidity & Leverage Metrics
Clene Inc. Total Liabilities Ratios Explained
Clene Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clene Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clene Inc. (2018–2025)
The table below shows the annual total liabilities of Clene Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $35.72 Million | -1.30% |
| 2024-12-31 | $36.19 Million | -7.08% |
| 2023-12-31 | $38.95 Million | -5.59% |
| 2022-12-31 | $41.26 Million | -18.25% |
| 2021-12-31 | $50.47 Million | -25.68% |
| 2020-12-31 | $67.90 Million | +579.70% |
| 2019-12-31 | $9.99 Million | -76.31% |
| 2018-12-31 | $42.16 Million | -- |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral … Read more